Ratings iCAD, Inc.

Equities

ICAD

US44934S2068

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.47 ^USD	-0.68%		-4.55%	-16.95%

Apr. 11	ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium	CI
Apr. 09	ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
ICAD, INC.	-16.95%	38.74M	D+
THERMO FISHER SCIENTIFIC	+8.07%	219B	B
DANAHER CORPORATION	+6.59%	183B	B-
INTUITIVE SURGICAL, INC.	+11.26%	133B	B-
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B	B+
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B	A
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B	-
RESMED, INC.	+26.76%	32.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes